U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H30N4O2S.ClH
Molecular Weight 463.036
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PEROSPIRONE HYDROCHLORIDE

SMILES

Cl.[H][C@@]12CCCC[C@]1([H])C(=O)N(CCCCN3CCN(CC3)C4=NSC5=C4C=CC=C5)C2=O

InChI

InChIKey=HIZFAPMOZFYELI-GNXQHMNLSA-N
InChI=1S/C23H30N4O2S.ClH/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21;/h3-4,9-10,17-18H,1-2,5-8,11-16H2;1H/t17-,18+;

HIDE SMILES / InChI

Molecular Formula C23H30N4O2S
Molecular Weight 426.575
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12054062

Perospirone (Lullan®) is an atypical antipsychotic of the azapirone family. It is used in Japan for the treatment of schizophrenia and acute cases of bipolar mania. Its primary mode of action is through antagonism of serotonin 5-HT2A and dopamine D2 receptors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.6 nM [Kd]
0.09 nM [Kd]
1.3 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
LULLAN

Approved Use

For the treatment of schizophrenia and acute cases of bipolar mania.

Launch Date

2000
Palliative
LULLAN

Approved Use

For the treatment of schizophrenia and acute cases of bipolar mania.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
1975 Nov
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
1992 Apr 10
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
1998 Mar
Patents

Sample Use Guides

The recommended dose is 4 mg three times daily taken after meals, and daily dose should not exceed 48 mg.
Route of Administration: Oral
In Vitro Use Guide
The binding affinity of perospirone (SM-9018) for various neurotransmitter and drug-receptors was investigated in the rat brain. SM-9018 possessed very high affinity for 5-HT2, D2 and 5-HT1A receptors (Ki = 0.61, 1.4 and 2.9 nM, respectively), and it had moderate affinity for alpha 1 and D1 receptors (Ki = 17 and 41 nM, respectively). However, SM-9018 had only negligible affinity for alpha 2, opiate, glutamate, phencyclidine, benzodiazepine and GABA-A receptors.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:09:57 GMT 2023
Edited
by admin
on Fri Dec 15 19:09:57 GMT 2023
Record UNII
T884I76TMN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PEROSPIRONE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
CIS-N-(4-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)BUTYL)-1,2-CYCLOHEXANEDICARBOXIMIDE HYDROCHLORIDE
Common Name English
SM-9018
Code English
Perospirone hydrochloride [WHO-DD]
Common Name English
PEROSPIRONE HYDROCHLORIDE [MI]
Common Name English
PEROSPIRONE HYDROCHLORIDE [MART.]
Common Name English
1H-ISOINDOLE-1,3(2H)-DIONE, 2-(4-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL)BUTYL)HEXAHYDRO-, HYDROCHLORIDE (1:1), (3AR,7AS)-REL-
Common Name English
Code System Code Type Description
MERCK INDEX
m8566
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY Merck Index
EVMPD
SUB20687
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
FDA UNII
T884I76TMN
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID9046449
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
SMS_ID
100000086466
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
PUBCHEM
115367
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
CAS
129273-38-7
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
MESH
C065533
Created by admin on Fri Dec 15 19:09:57 GMT 2023 , Edited by admin on Fri Dec 15 19:09:57 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY